Responses
Poster Presentations
Spondyloarthritis - treatment
THU0393 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies
Compose a Response to This Article
Other responses
No responses have been published for this article.